Dr. @PeterYuMD@nyulangone presents KRAS ctDNA monitoring in patients receiving daraxonrasib, with a 45% reported RAS ctDNA clearance rate and NYU cohort data showing KRAS ctDNA was detected in 60% at baseline and 40% clearance on follow-up.
The key question: Does early KRAS ctDNA clearance on daraxonrasib associate with clinical efficacy, including ORR and PFS? #DAVAGI #BermudaGI2026
Pulling out all the stops vs pancreatic cancer.
The recent FDA-approved, celebrated drug daraxonrasib, increased median survival by 6.5 months @RevMedicines
That's a positive step but clearly not enough. This new @Cancer_Cell paper lays out a path for more.
https://t.co/i3Kb8fEDzm
Congratulations to @Perlmutter_CC physician scientist @PeterYuMD on submitting his K08 grant on novel resistance mechanisms to KRAS inhibitors in #PancreaticCancer.
Now it’s 🍪 time!
Grateful for the opportunity to give a lightning presentation at #AACRpac23! Thank you to the organizers, as well as #AlecKimmelman and Kimmelman lab, @SAAswim, @NYUGSOM_HemeOnc, #perlmutter cancer center
1/ Grant-writing tips. This #tweetorial mainly applies to @NIH grants (particularly R01s) but some stuff may be applicable to other types of grants and funding agencies. Based on my experience writing grants for 20 yrs +lots of cringe-worthy missteps and rejections along the way!
Kudos to Dr. Alec Kimmelman on a $1.7 million Drug Discovery Award from @TheMarkFdn. He & Dr. Seth Parker @UBC will work to ID molecules that inhibit the amino acid transporter SLC38A2, a novel target for #pancreaticcancer@nyugrossman@NYULH_RadOnc
https://t.co/JkldKWxe8E
Thanks to Liz, @ConquerCancerFd, @SAAswim, and my mentor Alec Kimmelman for this Young Investigator Award. Working hard so we can improve outcomes for patients like Ted.
Olympic swimmer 🏊 @ebeisel34 partnered with @SAAswim to fund a young investigator award in memory of her dad who died from pancreatic cancer.
In this @ASCO podcast, Liz & our researcher Dr. Peter Yu reflect on why it matters to accelerate research.
🎧 https://t.co/j2LpF1vLpU